ИСТИНА

Prostate cancer (PC) is a major cause of cancer-related deaths in men worldwide. Localized prostate cancer in some cases is characterized by slow development and often overtreated. Patients within this clinical category have different risks of recurrence and different prognosis. Our study devoted to identifying novel prognostic biomarkers for localized PC, which will lead to optimization of treatment and development of appropriate clinical recommendations. Expression of 4 genes (CYP17A1, FAM72D, UBE2C, ESM1) were increased in the group of intermediate risk, and 6 genes (TCN1, SERPINA3, HP, MMP7, S100A9, FCN1) demonstrated decreased expression. These potential markers are involved in the formation and maintenance of the extracellular matrix (MMP7, S100A9, FCN1, SERPINA3, ESM1), metabolism (CYP17A1), cell cycle (UBE2C), neuronal formation (FAM72D), congenital immune response (FCN1), proteolysis (HP, FCN1, MMP7, S100A9, UBE2C, SERPINA3) and inflammation (SERPINA3, S100A9, HP). Disruption of all these processes is indicated for various types of cancer. After validation on the extended cohort these genes could be used in diagnostic panel for prognosis of localized prostate cancer to select an optimal treatment for an individual patient. Thus, we identified a number of genes as potential prognostic biomarkers associated with poor prognosis of localized PC.